Big Revenues and Big Expectations in Molecular IVD
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 01/15/13 -- Molecular diagnostics has seen extremely fast revenue growth in the past twelve years, according to Kalorama Information, but increasingly those revenues are coming along with demands from customers. The healthcare market research publisher says that molecular-based test products developed from the discoveries of the Human Genome Project are the fast growth area of in vitro diagnostics, but makers need to keep innovating. From a $940 million market in 2000, Kalorama estimates the 2012 market at $5,297 million, according to Kalorama Information's latest report on molecular diagnostics, "The World Market for Molecular Diagnostics, 5th Edition."
For the past 5 years the number of assays introduced has been growing at a remarkable clip. With the increased market penetration of molecular assays, demand will decrease the cost of commercialized kits and the need for standardization will make commercial kits more attractive, especially for small labs. But with that growth comes new demands from customers, according to the report's author, including more tests on the same platform.
"There is a demand for a large menu of tests available on a single platform since molecular tests must account for variability in test targets," said Shara Rosen, the author of the report. "But the tests must have high sensitivity for analytes in very small concentration, be quantitative and must use small whole blood, urine, saliva, and CSF samples."
Rosen states that there is a demand for test systems that are easy to use by non-laboratory and laboratory personnel. Sample collection-to-results, she says, is a key trend that customers will come to expect. It is anticipated as the prerequisite technology advancement to providing molecular testing in small laboratories and resource limited test sites anywhere in the world.
"The holy grail for molecular testing is the ability to load an untreated sample onto a cartridge or cassette, push start and then come back when the test has been completed," Rosen said.
According to the report, companies including Cepheid, Spartan, Qiagen, Hologic, GenMark, and Enigma have developed table top systems that offer small to medium sized labs the opportunity to run their own molecular tests.
Over 200 molecular companies were significant enough to be profiled in Kalorama's 850 page report, "The World Market for Molecular Diagnostics, 5th Edition." The report tiers these companies according to size and innovations made. It also contains breakouts for molecular diagnostics testing segments, offers revenues by region, reviews products in the marketplace, and more. Information on the report can be obtained at Kalorama Information's website at .
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on , and our .
Bruce Carlson
237 W. 35th Street
New York, NY 10001
212.807.2622 t
240.747.3004 f
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.01.2013 - 10:53 Uhr
Sprache: Deutsch
News-ID 1187336
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Information Services
Anmerkungen:
Diese Pressemitteilung wurde bisher 148 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Big Revenues and Big Expectations in Molecular IVD
"
steht unter der journalistisch-redaktionellen Verantwortung von
Kalorama Information (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
